Enveda raises $311M for nature-derived AI drug development

VERA Brief

AI-generated. Grounded in the article and its cited sources.

AI biotech firm Enveda has raised $311 million in a funding round that valued the company at $2 billion. The company is using artificial intelligence to develop nature-derived drug candidates for conditions such as skin issues and weight loss maintenance.

Key facts

• Enveda has raised $311 million in a funding round.
• The company was valued at $2 billion in the funding round.
• Enveda focuses on developing nature-derived drugs using artificial intelligence.
• The company is testing drug candidates for skin conditions and for maintaining weight loss.
• The firm's approach uses AI to identify and develop novel compounds from natural sources.